首页> 外文期刊>Maturitas: International Journal for the Study of the Climacteric >Breast cancer molecular subtypes - Modern therapeutic concepts for targeted therapy of a heterogeneous entity
【24h】

Breast cancer molecular subtypes - Modern therapeutic concepts for targeted therapy of a heterogeneous entity

机译:乳腺癌分子亚型-异质实体靶向治疗的现代治疗概念

获取原文
获取原文并翻译 | 示例
           

摘要

Within the last decade, breast cancer is increasingly understood as a heterogeneous disease comprising distinct entities that vary significantly with regard to molecular biology and clinical features. Despite impressive advances in the treatment of patients with breast cancer, not all patients derive equal benefits from current therapeutic options and a significant number of patients still experience disease recurrence. Whereas for patients with hormone receptor positive and/or HER2eu-positive breast cancer overcoming resistance against endocrine and/or anti-HER2eu-targeted therapy is of particular importance, patients with triple negative breast cancer suffer from a lack of sufficient targeted therapeutic options at all. In this review we give a summary of the most important targeted agents recently or currently being developed for patients with breast cancer.
机译:在过去的十年中,人们越来越多地将乳腺癌理解为一种异质性疾病,其中包括在分子生物学和临床特征方面差异很大的不同实体。尽管在乳腺癌患者的治疗方面取得了令人瞩目的进步,但是并不是所有的患者都能从当前的治疗方法中获得同等的收益,并且仍然有相当多的患者经历疾病复发。对于激素受体阳性和/或HER2 / neu阳性乳腺癌患者来说,克服针对内分泌和/或抗HER2 / neu靶向治疗的耐药性尤为重要,而三阴性乳腺癌的患者则缺乏足够的靶向性根本没有治疗选择。在这篇综述中,我们总结了最近或当前针对乳腺癌患者开发的最重要的靶向药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号